23andMe Holding Co. (ME)

NASDAQ: ME · IEX Real-Time Price · USD
5.18
-0.23 (-4.25%)
At close: Jan 14, 2022 4:00 PM
5.15
-0.03 (-0.58%)
After-hours:Jan 14, 2022 7:59 PM EST
Market Cap2.39B
Revenue (ttm)358.36M
Net Income (ttm)-242.16M
Shares Out461.37M
EPS (ttm)-1.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,488,122
Open5.28
Previous Close5.41
Day's Range4.92 - 5.37
52-Week Range4.92 - 18.16
Betan/a
AnalystsBuy
Price Target11.50 (+122.0%)
Earnings DateNov 10, 2021

About ME

23andMe Holding Co. operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. It has a ...

IndustryDiagnostics & Research
Founded2006
Employees572
Stock ExchangeNASDAQ
Ticker SymbolME
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ME stock is "Buy." The 12-month stock price forecast is 11.50, which is an increase of 122.01% from the latest price.

Price Target
$11.50
(122.01% upside)
Analyst Consensus: Buy

News

23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker

The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation The clearance a...

5 days ago - GlobeNewsWire

23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors

23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells

1 week ago - GlobeNewsWire

23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants

SUNNYVALE, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the results of the completed redempti...

2 weeks ago - GlobeNewsWire

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

These smaller healthcare companies all have 10x potential for investors.

Other symbols:MEDPMLAB
3 weeks ago - The Motley Fool

2 Cheap Stocks With 10X Potential to Buy in 2022

These two companies have massive growth opportunities and have declined sharply in recent months.

Other symbols:GSK
4 weeks ago - The Motley Fool

3 Top IPO Stocks to Put on Your Watchlist

Not all IPO stocks are created equal.

Other symbols:ABNBLZ
1 month ago - The Motley Fool

Like Strong Balance Sheets? These 3 Stocks Are Loaded With Cash

With these kinds of resources, these companies are becoming less-risky investments.

Other symbols:POSHRSKD
1 month ago - The Motley Fool

Why 23andMe Stock Dropped 29% in November

The company reported disappointing earnings results and has fallen victim to the recent sell-off in high-growth stocks.

1 month ago - The Motley Fool

Anne Wojcicki's 23andMe Fortune Falls Under $1 Billion As Shares Sink Post-IPO

Her genetics testing company is the latest to flounder after going public via SPAC.

1 month ago - Forbes

23andMe Announces the Appointment of Joseph R. Arron, M.D.

Dr. Arron brings nearly two decades of scientific leadership in biotech drug discovery and development to 23andMe's Therapeutics team Dr. Arron brings nearly two decades of scientific leadership in biot...

1 month ago - GlobeNewsWire

23andMe Announces Redemption of All Outstanding Warrants

SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its outsta...

1 month ago - GlobeNewsWire

Why 23andMe Stock Crashed 10% Today

Last week's good news for the genetic data miner wasn't as good as it looked.

2 months ago - The Motley Fool

23andMe CEO says health is the ultimate driver of her company's long-term growth

Anne Wojcicki, 23andme CEO, joins 'Closing Bell' to discuss its second quarter earnings report and what's driving growth for the company long-term.

2 months ago - CNBC Television

Why 23andMe Stock Scored an 11% Gain Today

23andMe lost a lot less money than feared today -- so why is it sticking with a prediction for a full-sized loss for the year?

2 months ago - The Motley Fool

23andMe Reports FY2022 Second Quarter Financial Results

Second quarter revenue of $55 million Recent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives

2 months ago - GlobeNewsWire

23andMe to Present at Upcoming Virtual Healthcare Conferences

SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, announced today that management will be presenting at thre...

2 months ago - PRNewsWire

23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors

SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, today announced the appointment of Dr. Sandra Hernández, P...

2 months ago - PRNewsWire

23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for...

SUNNYVALE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results...

2 months ago - GlobeNewsWire

Why 23andMe Rocketed 27.9% Higher in October

The genetics upstart is acquiring a telehealth platform.

2 months ago - The Motley Fool

23andMe Announces the Closing of its Acquisition of Lemonaid Health

SUNNYVALE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its previously-...

2 months ago - GlobeNewsWire

Why 23andMe Stock Was Up More Than 9% on Tuesday

Investors may see potential in the company's proposed acquisition of telehealth company Lemonaid.

2 months ago - The Motley Fool

23andMe to Buy Web Platform Lemonaid Health for $400M

Hims & Hers Health has had its biggest one-day loss in over two months, following its rival 23andMe's agreement to buy web-based healthcare platform Lemonaid Health. Hims & Hers is a telehealth platform...

2 months ago - PYMNTS

23andme CEO on deal to buy Lemonaid: I love Lemonaid for the pharmacy component

23andme CEO Anne Wojcicki joins The Exchange to discuss her company's planned acquisition of Lemonaid, a telehealth company, and the future of genetic integration in health. For access to live and exclu...

2 months ago - CNBC Television

Why 23andMe Stock Dropped Today

Fresh off its SPAC IPO, 23andMe is buying another company.

2 months ago - The Motley Fool

23andMe to buy telehealth firm Lemonaid for $400 million

Direct-to-consumer DNA testing firm 23andMe Holding Co said on Friday it would buy privately held company Lemonaid Health Inc for $400 million in a cash-and-stock deal, as it looks to expand into teleme...

2 months ago - Reuters